pritumumab
mAbexperimental
Pritumumab (PTB) is a human monoclonal antibody targeted against glioma. It works by binding to the ecto-domain of vimentin on the surface of cancer cells. developed by Nascent Biotech. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2020 (NCT04396717)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- VimentinINHIBITOR
VIM inhibitor
- VimentinOTHER
VIM other
Antibody dependent cell-mediated cytotoxicity, Complement Dependent Cytotoxicity, Natural Killer Cell-induction.
Affinity of pritumumab for its antigen (expressed on U-251MG cell-line) is 4.5×10¿7 M
Reactive epitope is located in the c2 (coil 2 of the central rod) domain of vimentin.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPritumumab ↗
- ChEMBLCHEMBL2108045 ↗
Also known as
- pritumumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04396717 | Phase 1 | Jun 30, 2020 | Hoag Memorial Hospital Presbyterian, Nascent Biotech |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hoag Memorial Hospital Presbyterian | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Nascent Biotech | For profit | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1